New hope: targeted pill before surgery for lung cancer patients
NCT ID NCT03433469
First seen Apr 04, 2026 · Last updated Apr 29, 2026 · Updated 4 times
Summary
This study tests whether the drug osimertinib, taken before surgery, can shrink tumors in people with early-stage non-small cell lung cancer that has a specific gene mutation (EGFR). About 27 adults with stage I to IIIA disease will receive the drug before their operation. The main goal is to see how many patients have a major reduction in live tumor cells after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California, Davis
Davis, California, 95864, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.